Benzinga · Oct 30, 2026
Otsuka Holdings Sees FY2026 GAAP EPS of JPY 703.91 and Revenue of JPY 2,725B
Otsuka Holdings (OTC:OTSKY) Sees FY2026 GAAP EPS of JPY 703.91 and Revenue of JPY 2,725B
OT
NYSE · OTSKY
Otsuka Holdings Co., Ltd.
Healthcare · Drug Manufacturers - General
$37.98
Up+$1.06 (+2.87%)
Updated Nov 5, 2026, 12:42 AM
SID Score
6.0/10
Composite research score
Smart Money
46/100
Neutral
- Market cap
- 32.85B
- P/E ratio
- 10.98
- Dividend yield
- 1.15%
- 52-week range
- — – —
- Volume
- 31.85K
- Avg. volume
- 37.4K
Price performance · OTSKY
OTSKY price history
1M range · 0 trading sessions · Daily adjusted prices
OTSKY does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest OTSKY news
The latest Smart Investors Daily articles mentioning OTSKY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
OTSKY research
Overview
Company profile and research snapshot.
Company profile
OTSUKA HOLDINGS CO ADR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Oct 30, 2026
Otsuka Holdings Q3 EPS $0.64 Down From $0.74 YoY, Sales $4.461B Miss $4.470B Estimate
Otsuka Holdings (OTC:OTSKY) reported quarterly earnings of $0.64 per share. This is a 13.51 percent decrease over earnings of $0.74 per share from the same period last year. The company reported quarterly sales of
SeekingAlpha · Aug 6, 2026
Otsuka Holdings Co., Ltd. (OTSKY) Discusses 24-Month eGFR Results of Sibeprenlimab in IgA Nephropathy from Phase III VISIONARY Study - Slideshow
2026-08-06. The following slide deck was published by Otsuka Holdings Co., Ltd.
SeekingAlpha · Aug 6, 2026
Otsuka Holdings Co., Ltd. (OTSKY) Discusses 24-Month eGFR Results of Sibeprenlimab in IgA Nephropathy from Phase III VISIONARY Study Prepared Remarks Transcript
Otsuka Holdings Co., Ltd. (OTSKY) Discusses 24-Month eGFR Results of Sibeprenlimab in IgA Nephropathy from Phase III VISIONARY Study August 3, 2026 8:01 PM...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
